6978 Stock Overview
A cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Immunotech Biopharm Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.24 |
| 52 Week High | HK$6.15 |
| 52 Week Low | HK$1.50 |
| Beta | 0.93 |
| 1 Month Change | -20.98% |
| 3 Month Change | 0% |
| 1 Year Change | 5.88% |
| 3 Year Change | -35.20% |
| 5 Year Change | n/a |
| Change since IPO | -79.07% |
Recent News & Updates
Shareholder Returns
| 6978 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -9.2% | 13.0% | 1.6% |
| 1Y | 5.9% | 64.2% | 14.8% |
Return vs Industry: 6978 underperformed the Hong Kong Biotechs industry which returned 58.4% over the past year.
Return vs Market: 6978 underperformed the Hong Kong Market which returned 14% over the past year.
Price Volatility
| 6978 volatility | |
|---|---|
| 6978 Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 13.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6978's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6978's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 154 | Yu Wang | www.eaal.net |
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma; and TCR-T cell series products to treat solid tumors.
Immunotech Biopharm Ltd Fundamentals Summary
| 6978 fundamental statistics | |
|---|---|
| Market cap | HK$1.67b |
| Earnings (TTM) | -HK$203.16m |
| Revenue (TTM) | n/a |
Is 6978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6978 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥186.91m |
| Earnings | -CN¥186.91m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -1,629.5% |
How did 6978 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 07:02 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunotech Biopharm Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lok Kwan Chiu | CCB International Securities Limited |
| Yidong Zhang | Industrial Securities (HK) Financial Holdings |
| Qianlan Zhu | SPDB International Holdings Limited |